Comparative Pharmacology
Head-to-head clinical analysis: DRAXIMAGE MDP 25 versus TECHNESCAN HDP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRAXIMAGE MDP 25 versus TECHNESCAN HDP.
DRAXIMAGE MDP-25 vs TECHNESCAN HDP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium-99m methylene diphosphonate (MDP) is a bone-seeking radiopharmaceutical. After intravenous injection, it adsorbs onto hydroxyapatite crystals in bone, with increased uptake in areas of high metabolic activity or blood flow, such as tumors or fractures. The technetium-99m emits gamma rays which are detected by a gamma camera for imaging.
Technetium Tc-99m oxidronate (HDP) is a bone-seeking radiopharmaceutical that localizes to areas of osteoblastic activity. It binds to hydroxyapatite crystals in bone via chemisorption, allowing scintigraphic imaging of skeletal lesions.
555–925 MBq (15–25 mCi) intravenously for bone scintigraphy; imaging performed 2–4 hours post-injection
For bone scintigraphy: 740 MBq (20 mCi) intravenous injection.
None Documented
None Documented
Terminal elimination half-life is approximately 6-8 hours for the primary complex; minor radiochemical impurities may have longer half-lives
Terminal elimination half-life is approximately 2-3 hours for the diphosphonate component, with clinical imaging typically performed 2-4 hours post-injection.
Primarily renal (urinary excretion of 60-70% as unchanged drug within 24 hours, with 5-10% biliary excretion)
Renal: >95% excreted unchanged in urine within 24 hours. Biliary/fecal: <5%.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical